KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Expenses (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Operating Expenses readings, the most recent being $146.2 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 7.44% to $146.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $533.8 million, a 17.78% increase, with the full-year FY2025 number at $533.8 million, up 17.78% from a year prior.
  • Operating Expenses hit $146.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from $129.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $146.2 million in Q4 2025 to a low of $70.4 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $101.9 million (2023), compared with a mean of $108.8 million.
  • Biggest five-year swings in Operating Expenses: soared 92.22% in 2021 and later decreased 2.69% in 2023.
  • Biocryst Pharmaceuticals' Operating Expenses stood at $99.3 million in 2021, then grew by 26.7% to $125.9 million in 2022, then increased by 8.12% to $136.1 million in 2023, then decreased by 0.02% to $136.0 million in 2024, then grew by 7.44% to $146.2 million in 2025.
  • The last three reported values for Operating Expenses were $146.2 million (Q4 2025), $129.8 million (Q3 2025), and $133.6 million (Q2 2025) per Business Quant data.